ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0196

Increasing Timely Rheumatology Evaluation for High Risk Lupus Patients

Steven Taylor1 and Elena Weinstein2, 1University of Colorado, Denver, CO, 2University of Colorado, Englewood, CO

Meeting: ACR Convergence 2025

Keywords: Access to care, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 26, 2025

Title: (0175–0198) Health Services Research Poster I

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: The rheumatology workforce shortage presents many challenges to the delivery of rheumatology care. Improving timely access to rheumatology for patients with life or organ threatening conditions such as SLE is one of the most important challenges. Our institution has a significant mismatch between number of referrals for new evaluation and number of new patient spots within our clinic. Further complicating the challenge of scheduling a prompt evaluation for these patients is the complex and multisystem nature of SLE. Literature suggests less than half of these referrals have inflammatory rheumatic disease (Feuchtenberger, 2016) and delays in SLE care lead to worse outcomes (Kernder, 2021). Therefore, we developed a quality improvement (QI) project to improve the time from referral to first rheumatology appointment, in this report we describe the results of our first iteration of the project.

Methods: Our study was deemed IRB exempt as a QI initiative. We implemented the Model for Improvement framework in our project (Langley, 2009). The aim statement of the project is to reduce the time from referral entry to first visit with a rheumatologist by 20% in which a diagnosis of SLE is coded. Data was collected from the medical record including ICD10 codes associated with the initial visit, date of initial visit, and date of the referral order. The first Plan, Do, Act, Study (PDSA) cycle focused on referral management. In the baseline state referrals were evaluated by a registered nurse (RN) reviewing the chart for appropriateness for rheumatology visit. That protocol did not include a mechanism to identify high risk phenotypes. Therefore, the referral process was changed to a hybrid of RN and rheumatologist review. The rheumatologist was instructed to evaluate appropriateness of referral and to risk stratify timing of the appointment. Statistical analysis was performed in R, tests of significance were Student’s T and Mann-Whitney-Wilcoxon.

Results: The first PDSA cycle was started in February of 2024, with the addition of physician review on February 19th. From October 1, 2023, to July 1, 2024, there were 4,405 referrals to rheumatology, of which 123 had a diagnosis of SLE on the first visit. The median time from referral order to first appointment was 60.5 (±59.2) days for all referrals, and 60 (±57.2) days for SLE appointments. From October 1 to February 19 the median time to appointment was 70 (±67.3) days (n 707), and from February 19 to July 31 it is 5a5 (±42.5) days (n 539) p≤0.05. For SLE appointments the median time to appointment was 69±63 days (n 73) before intervention while the time after intervention was 51±38.9 (n 50) p≤0.05. A run chart for monthly time to evaluation is included in figure 1.

Conclusion: By incorporating physician review into the referral evaluation process, we were able to decrease the time to appointment by 26% for SLE patients. Confounding our study was an expansion of our clinical faculty in January 2024 and April 2024 by 1 full time equivalent. The next iterations of our project will focus on alternative processes to further improve access for patients with high-risk disease states while reducing reliance on manual chart review. This is an area of critical need in rheumatology.

Supporting image 1Run Chart of monthly days until rheumatology appointment for lupus patients


Disclosures: S. Taylor: None; E. Weinstein: AbbVie/Abbott, 5, Amgen, 5, Argenx, 5, Immunovant, 5, Priovant, 5, UCB, 5.

To cite this abstract in AMA style:

Taylor S, Weinstein E. Increasing Timely Rheumatology Evaluation for High Risk Lupus Patients [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/increasing-timely-rheumatology-evaluation-for-high-risk-lupus-patients/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/increasing-timely-rheumatology-evaluation-for-high-risk-lupus-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology